|

Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.

RECRUITINGN/ASponsored by Universitaire Ziekenhuizen KU Leuven
Actively Recruiting
PhaseN/A
SponsorUniversitaire Ziekenhuizen KU Leuven
Started2026-05-26
Est. completion2030-04
Eligibility
Age55 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07666113

Summary

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns. Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

Eligibility

Age: 55 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.

Exclusion Criteria:

* Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
* Concomitant medications that would interfere with cognitive assessments.
* A prior diagnosis of AD and related disorders or other neurodegenerative disease.

Conditions2

Alzheimer's DiseaseAlzheimer's Disease (AD)

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.